Purpose: The objective of this study was to evaluate the effects of intratunical injection of platelet rich plasma (PRP) for the treatment of Peyronie’s disease (PD) in a rat model. Materials and Methods: Twenty male Sprague-Dawley rats (300–350 g) were randomly divided into 4 groups: sham, PD, PD + PRP, and PRP. The PD + PRP groups received intratunical injections with 0.1 mL PRP on day 15 (treatment) or day 0 (PRP effect). Forty-five days following transforming growth factor-beta 1 injection, rats underwent pathological examination. Tissues were evaluated histologically for fibrosis grade (Haematoxylin & Eosin staining), collagen/smooth muscle ratio (Masson Trichrome staining) and type III/type I collagen ratio (Picro-sirius red staining). Statistical analysis was performed by Kruskal-Wallis and chi-square followed by the Mann-Whitney U test for post hoc comparisons. Results: Significant changes were found in all 3 groups compared to the sham group (p < 0.0001 for fibrosis, p = 0.001 for collagen/smooth muscle ratio and p = 0.003 for type III/type I collagen ratio). The values in the PRP group and the findings in the PD group are similar (p = 0.122 for fibrosis, p = 0.221 for collagen/smooth muscle ratio and p = 1.0 for type III/type I collagen ratio). Conclusion: This is the first study of PRP on PD. As a result of pathological examinations, PRP shows PD-like effects in rats. PRP may be a cheap, easily accessible, and an effective disease model for PD treatment research.

Keywords:
Peyronie’s Disease, Platelet-rich plasma, Rat model, Fibrosis, Transforming growth factor-beta
1.
Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X: A population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol 2011: 282503.
2.
Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, Davis R, Hellstrom W: Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol 2004; 171(6 pt 1): 2350–2353.
3.
La Pera G, Pescatori ES, Calabrese M, Boffini A, Colombo F, Andriani E, Natali A, Vaggi L, Catuogno C, Giustini M, Taggi F: Peyronie’s disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50–69 years. Eur Urol 2001; 40: 525–530.
4.
Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT: The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991; 146: 1007–1009.
5.
Devine CJ, Jr., Somers KD, Jordan SG, Schlossberg SM: Proposal: trauma as the cause of the Peyronie’s lesion. J Urol 1997; 157: 285–290.
6.
Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. New Engl J Med 1994; 331: 1286–1292.
7.
Diegelmann RF: Cellular and biochemical aspects of normal and abnormal wound healing: an overview. J Urol 1997; 157: 298–302.
8.
Mulhall JP, Thom J, Lubrano T, Shankey TV: Basic fibroblast growth factor expression in Peyronie's disease. J Urol 2001; 165: 419–423.
9.
Ralph D, Gonzalez-Cadavid N, Mirone V, Perovic S, Sohn M, Usta M, Levine L: The management of Peyronie’s disease: evidence-based 2010 guidelines. J Sex Med 2010; 7: 2359–2374.
10.
Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT: Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004; 91: 4–15.
11.
Einhorn TA: The cell and molecular biology of fracture healing. Clin Orthop Relat Res 1998 (355 suppl):S7–S21
12.
Eppley BL, Woodell JE, Higgins J: Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg 2004; 114: 1502–1508.
13.
Marx RE: Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 2004; 62:: 489–496.
14.
Sanchez AR, Sheridan PJ, Kupp LI: Is platelet-rich plasma the perfect enhancement factor? A current review. Int J Oral Maxillofac Implants 2003; 18: 93–103.
15.
Garg AK: The use of platelet-rich plasma to enhance the success of bone grafts around dental implants. Dent Implantol Update 2000; 11: 17–21.
16.
Pietrzak WS, Eppley BL: Platelet rich plasma: biology and new technology. J Craniofac Surg 2005; 16: 1043–1054.
17.
Woodall J Jr, Tucci M, Mishra A, Asfour A, Benghuzzi H: Cellular effects of platelet rich plasmainterleukin1 release from prp treated macrophages. Biomed Sci Instrum 2008; 44: 489–494.
18.
El-Sakka AI, Hassan MU, Nunes L, Bhatnagar RS, Yen TS, Lue TF: Histological and ultrastructural alterations in an animal model of Peyronie’s disease. Br J Urol 1998; 81: 445–452.
19.
Piao S, Ryu JK, Shin HY, Zhang L, Song SU, Han JY, Park SH, Kim JM, Kim IH, Kim SJ, Suh JK: Repeated intratunical injection of adenovirus expressing transforming growth factor-beta1 in a rat induces penile curvature with tunical fibrotic plaque: a useful model for the study of Peyronie’s disease. International journal of andrology 2008; 31: 346–353.
20.
El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF: An animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997l; 158: 2284–2290.
21.
Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF: Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie’s disease. BJU Int 2006; 97: 625–633.
22.
Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF: Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie’s disease. BJU Int 2003; 91 9: 830–838.
23.
Gokce A, Abd Elmageed ZY, Lasker GF, Bouljihad M, Kim H, Trost LW, Kadowitz PJ, Abdel-Mageed AB, Sikka SC, Hellstrom WJ: Adipose tissue-derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie’s disease. Andrology 2014; 2 (2): 244–251.
24.
Sohn DW, Bae WJ, Kim HS, Kim SW, Kim SW: The anti-inflammatory and antifibrosis effects of anthocyanin extracted from black soybean on a Peyronie disease rat model. Urology 2014; 84: 1112–1116.
25.
Chung E, Garcia F, Young LD, Solomon M, Brock GB: A comparative study of the efficacy of intralesional verapamil versus normal saline injection in a novel Peyronie -disease animal model: assessment of immunohistopathological changes and erectile function outcome. J Urol 2013; 189: 380–384.
26.
Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, Jones N, Kaufman GJ, Carson CC 3rd: Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013; 190: 199–207.
27.
Lipshultz LI, Goldstein I, Seftel AD, Kaufman GJ, Smith TM, Tursi JP, Burnett AL: Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie'’ disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU international 2015; 116: 650–656.
28.
Beye JA, Hart DA, Bray RC, McDougall JJ, Salo PT: Injury-induced changes in mRNA levels differ widely between anterior cruciate ligament and medial collateral ligament. Am J Sports Med 32008; 6: 1337–1346.
29.
Hildebrand KA, Frank CB: Scar formation and ligament healing. Can J Surg 1998; 41: 425–429.
30.
Wu CC, Wu YN, Ho HO, Chen KC, Sheu MT, Chiang HS: The neuroprotective effect of platelet-rich plasma on erectile function in bilateral cavernous nerve injury rat model. J Sex Med 2012; 9: 2838–2848.
31.
Ding XG, Li SW, Zheng XM, Hu LQ, Hu WL, Luo Y: The effect of platelet-rich plasma on cavernous nerve regeneration in a rat model. Asian J Androl 2009; 11: 215–221.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.